Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy

Antisense oligonucleotides (ASOs) have emerged as one of the most innovative new genetic drug modalities. However, their high molecular weight limits their bioavailability for otherwise-treatable neurological disorders. We investigated conjugation of ASOs to an antibody against the murine transferri...

Full description

Bibliographic Details
Main Authors:	Suzan M. Hammond, Frank Abendroth, Larissa Goli, Jessica Stoodley, Matthew Burrell, George Thom, Ian Gurrell, Nina Ahlskog, Michael J. Gait, Matthew J.A. Wood, Carl I. Webster
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2022-12-01
Series:	JCI Insight
Subjects:	Neuroscience
Online Access:	https://doi.org/10.1172/jci.insight.154142

Similar Items

Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy
by: Hammond, S, et al.
Published: (2019)

Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy
by: Katharina E. Meijboom, et al.
Published: (2021-07-01)

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy
by: Shabanpoor, F, et al.
Published: (2017)

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
by: Hammond, S, et al.
Published: (2016)

Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect
by: Haiyan Zhou, et al.
Published: (2022-11-01)

Central synaptopathy is the most conserved feature of motor circuit pathology across spinal muscular atrophy mouse models
by: Jannik M. Buettner, et al.
Published: (2021-11-01)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
by: Corinne Betts, et al.
Published: (2012-01-01)

Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
by: Niba, Emma Tabe Eko, et al.
Published: (2022)

Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
by: Niba, Emma Tabe Eko, et al.
Published: (2022)

Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy
by: Meijboom, KE, et al.
Published: (2021)

Clinical characterizations of three adults with genetically confirmed spinal muscular atrophy: a case series
by: Setyaningrum, Cempaka Thursina Srie, et al.
Published: (2022)

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
by: Wood, M, et al.
Published: (2017)

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
by: Hammond, S, et al.
Published: (2010)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
by: Lisseth Estefania Burbano, et al.
Published: (2022-12-01)

CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy
by: Emily Foran, et al.
Published: (2016-04-01)

Model systems for exploring new therapeutic interventions and disease mechanisms in spinal muscular atrophies (SMAs)
by: Sleigh, JN
Published: (2012)

Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS
by: Meredith A. Mortberg, et al.
Published: (2022-03-01)

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
by: Jeffrey M Keil, et al.
Published: (2014-01-01)

Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.
by: Betts, C, et al.
Published: (2012)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
by: Betts, C, et al.
Published: (2012)

A pathogenic proteolysis–resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function
by: Hyeongju Kim, et al.
Published: (2022-09-01)

FXYD2 antisense oligonucleotide provides an efficient approach for long-lasting relief of chronic peripheral pain
by: Alexandre Derre, et al.
Published: (2023-05-01)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
by: Gait, M, et al.
Published: (2018)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
by: Tracy A. Cole, et al.
Published: (2021-03-01)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
by: Hammond, S, et al.
Published: (2011)

Downregulation of UBE4B promotes CNS axon regrowth and functional recovery after stroke
by: Shuang Jin, et al.
Published: (2023-01-01)

Nanocarriers for Delivery of Oligonucleotides to the CNS
by: David Male, et al.
Published: (2022-01-01)

C1q is essential for myelination in the central nervous system (CNS)
by: Qiang Yu, et al.
Published: (2023-12-01)

Transcriptomic atlas and interaction networks of brain cells in mouse CNS demyelination and remyelination
by: Jinchao Hou, et al.
Published: (2023-04-01)

High-efficiency pharmacogenetic ablation of oligodendrocyte progenitor cells in the adult mouse CNS
by: Yao Lulu Xing, et al.
Published: (2023-02-01)

Identifying epigenetic regulators of survival motor neuron protein to treat spinal muscular atrophy
by: Kordala, A
Published: (2022)

Mesyl phosphoramidate oligonucleotides as potential splice-switching agents: impact of backbone structure on activity and intracellular localization
by: Hammond, SM, et al.
Published: (2021)

Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease
by: Jeffrey R. Atkinson, et al.
Published: (2022-06-01)

Multifaceted roles of microRNAs: From motor neuron generation in embryos to degeneration in spinal muscular atrophy
by: Tai-Heng Chen, et al.
Published: (2019-11-01)

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model
by: Claudia Milazzo, et al.
Published: (2021-08-01)

Ataxia-linked SLC1A3 mutations alter EAAT1 chloride channel activity and glial regulation of CNS function
by: Qianyi Wu, et al.
Published: (2022-04-01)

HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART
by: Shelli F. Farhadian, et al.
Published: (2022-07-01)

Assessment of Nuclear Gem Quantity for Evaluating the Efficacy of Antisense Oligonucleotides in Spinal Muscular Atrophy Cells
by: Haya Al-Hilal, et al.
Published: (2024-01-01)

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene
by: Eric W Ottesen, et al.
Published: (2024-02-01)

Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice
by: Ahlskog, N, et al.
Published: (2020)